Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) – Can They be Better than ADCs?

Medicinal Chemistry and Chemical Biology Highlights

Authors

  • Karl-Heinz Altmann ETH Zurich, Department of Chemistry and Applied Biosciences, HCI H405, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland. karl-heinz.altmann@pharma.ethz.ch

DOI:

https://doi.org/10.2533/chimia.2018.154

Keywords:

Antibody-drug conjugates, Anticancer drug discovery, Small molecule-drug conjugates, Tumor targeting, Tumor uptake

Downloads

Published

2018-03-30